For forty years, cardiology has chased the wrong ghost: the visible blockage. Dr. Eric Topol argues that the field is finally pivoting toward the invisible killer—the inflamed, non-obstructive plaque that ruptures without warning. This isn't just a tweak in protocol; it is a fundamental rewrite of how we prevent heart attacks, driven by artificial intelligence that sees what the human eye cannot and a new generation of drugs that target inflammation rather than just cholesterol.
The Great Misdiagnosis
Dr. Eric Topol begins by dismantling the century-old obsession with "obstructive, blood flow-limiting narrowings." For decades, the medical community has relied on angiograms, which merely show a 2D silhouette of the artery's channel. "This year we've gotten signals that a major shift is ongoing, from fixation on obstructive coronary artery disease... to the focus on non-obstructive arterial disease," Topol writes. This reframing is critical because the most dangerous plaques often do not narrow the artery enough to trigger a stress test or appear severe on a standard scan.
The historical context here is stark. Topol notes that a 1996 editorial by Nobel laureates Michael Brown and Joseph Goldstein asked if heart attacks would be "Gone with the Century?" The answer, he points out, is a resounding no. Despite statins, the United States still sees over 800,000 heart attacks annually. The failure wasn't a lack of effort, but a lack of vision. "The challenge is to develop noninvasive screening methods to detect coronary atherosclerosis in its earliest stages," the 1996 editorial presciently noted. Topol argues we are only now building the tools to meet that challenge.
The pathology of a heart attack is rarely about a slow choke; it is a sudden explosion. Topol describes the "thin fibrous cap" of a vulnerable plaque, which is prone to cracking. Unlike stable plaque, these dangerous formations lack dense calcification, a fact that renders the common calcium score "highly misleading." He is blunt about this limitation: "This is one of the reasons I have never ordered a CT calcium score for any patient since they are often highly misleading." By focusing on the calcium, doctors were essentially looking for the aftermath of a fire while ignoring the spark.
The challenge is to develop noninvasive screening methods to detect coronary atherosclerosis in its earliest stages.
Critics might argue that shifting focus to non-obstructive disease could lead to over-treatment of patients who would never have had an event. However, Topol counters this by highlighting the PREVENT trial, a recent randomized study showing that intervening on these specific high-risk plaques significantly reduced major cardiovascular events compared to medication alone.
Seeing the Unseen with AI
The engine of this shift is the marriage of coronary computed tomography angiography (CCTA) with artificial intelligence. Topol details how four distinct companies are now using AI to detect features invisible to standard review. While some focus on plaque composition, Topol highlights CARISTO for its use of the fat attenuation index (FAI). This technology measures the inflammation in the fat tissue surrounding the artery, a process that correlates directly with the biological chaos inside the vessel wall.
The data is terrifyingly clear. Topol cites a study of 40,000 patients in the UK where the presence of a single inflamed artery raised the risk of death by 13-fold. "Even 1 inflamed artery raised the risk of death 13-fold compared with no inflamed arteries!" he writes. This statistic alone justifies the paradigm shift. It moves the conversation from "how blocked is the pipe?" to "how angry is the tissue?"
This technological leap has already triggered institutional change. Topol notes that Medicare recently announced reimbursement for these AI-enhanced scans at over $1,000 per procedure. "Another sign of a big shift," he observes. The financial infrastructure is finally aligning with the clinical reality that early detection of inflammation saves lives.
Beyond the Plaque: The Patient Problem
Despite the technological breakthroughs, Dr. Eric Topol issues a sharp critique of the current medical mindset. He warns against getting "far too much fixation on just the atheroma, the vulnerable plaque, instead of on the high-risk patient." We have the tools to see the plaque, but we are failing to identify the people most likely to harbor it. Topol advocates for a multi-layered approach that includes polygenic risk scores, which can predict risk independent of traditional factors like smoking or family history.
He also points to the retina as a window into the heart. "Our results indicate that one could identify patients at high risk of future myocardial infarction from retinal imaging available in every optician and eye clinic," he quotes from a recent study. This integration of data—genomics, proteins, and imaging—creates a comprehensive risk profile that a single scan cannot provide.
The drug pipeline is also expanding to match this new understanding. Topol lists a "rapidly expanding" toolkit including oral PCSK9 blockers, Lp(a) inhibitors, and anti-inflammatory drugs like interleukin blockers. He notes that GLP-1 drugs, often associated with weight loss, have shown heart attack reduction benefits that are "only about a third of the benefit was weight-loss dependent." This suggests the drugs are acting directly on the vascular biology, further validating the inflammation hypothesis.
The time is also ripe for the development of strategies to promote increased physician awareness of the crucial role of inflammation in CVD.
A counterargument worth considering is the sheer cost and complexity of integrating these new layers of data into routine care. While Topol argues the cost could be low, the logistical hurdle of coordinating genomics, AI imaging, and specialized blood work across fragmented health systems is immense. The technology is ready; the system is not.
Bottom Line
Dr. Eric Topol's argument is a powerful call to abandon the 20th-century model of treating heart disease as a plumbing problem and embrace a 21st-century view of it as an inflammatory, biological process. The strongest part of his case is the convergence of AI diagnostics, new reimbursement policies, and targeted therapies that finally allow us to see and treat the disease before it kills. However, the biggest vulnerability remains the gap between this scientific promise and the slow pace of clinical adoption. The tools to "create a world without heart attacks" exist, but as Topol concludes, "we have no indication of any shift in action."